Dermatology Products · LP-088
Benzyl benzoate Lotion
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-088Dermatology Products
- Generic identity
- Benzyl benzoateLotion
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-088
- Generic ingredient
- Benzyl benzoate
- Dosage form
- Lotion
- Proposed strength
- 25%
- Proposed pack
- Bottle 100 mL
- Portfolio category
- Dermatology Products
About Benzyl benzoate
Benzyl benzoate is a topical agent used in certain scabies-treatment settings. The formulation, concentration and age restrictions are important because skin irritation can be significant. It should not be confused with an oral antiparasitic medicine or a general skin disinfectant. This ingredient education does not establish Luang Pharma approved labeling, a dilution instruction or suitability of the proposed lotion for infants or sensitive skin.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Scabies management includes confirming the diagnosis and considering close contacts and reinfestation. Persistent itching after treatment does not necessarily mean the medicine has failed, but worsening rash or signs of secondary infection should be assessed. Crusted scabies and illness in vulnerable patients require professional management. WHO recognizes benzyl benzoate among topical options, but that does not validate an individual product. A clinician selects a locally authorized formulation and a complete management plan.
Important safety considerations
Benzyl benzoate can irritate skin and should be kept away from the eyes and mucous membranes. Broken or inflamed skin and young age need particular review. Accidental ingestion is potentially dangerous and warrants urgent advice. Do not improvise a dilution or mix the lotion with other chemicals. Severe burning, swelling, breathing difficulty or systemic symptoms requires assessment. The exact product information must define permitted application sites, precautions and any age-related restrictions.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
This presentation is a proposed topical lotion. The concentration, vehicle, permitted sites and age-related instructions must be established from the exact approved product information. A high-strength lotion should not be assumed to be ready for use in every patient or suitable for an improvised dilution.
Keep the container labeled and securely closed, and follow its actual mixing or application instructions. Do not decant into a food or drink container. Storage requirements, expiry and any preparation precautions depend on the supplied formulation; consult a professional if the label is unclear.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
A clinician or pharmacist should confirm the skin diagnosis, application site, extent and suitability of the exact formulation. Unexplained, spreading or recurrent lesions need assessment. Product-specific instructions determine age restrictions, handling and permitted use.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Benzyl benzoate
- Dosage form / presentation
- Lotion
- Catalogue strength
- 25%
- Catalogue pack
- Bottle 100 mL
- Portfolio category
- Dermatology Products
Layer 02
Unresolved product-specific fields
- WHO scabies page supports benzyl-benzoate topical clinical context. No improvised dilution, universal pediatric suitability or exact lotion vehicle is claimed.
- Exact vehicle/excipient system, intended application site and formulation-specific instructions require controlled product documentation.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- WHO: Scabies — diagnosis and topical treatment optionsWHO clinical public-health guidance
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-088, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-088.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.